Literature DB >> 19093126

[ANCA-associated vasculitides. Classifying the disease and its activity according to EULAR/EUVAS recommendations].

J U Holle1, P Lamprecht.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19093126     DOI： 10.1007/s00393-008-0418-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  8 in total

Review 1.  Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.

Authors:  D R Jayne; N Rasmussen
Journal:  Mayo Clin Proc       Date:  1997-08       Impact factor: 7.616

Review 2.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

3.  EULAR recommendations for the management of primary small and medium vessel vasculitis.

Authors:  C Mukhtyar; L Guillevin; M C Cid; B Dasgupta; K de Groot; W Gross; T Hauser; B Hellmich; D Jayne; C G M Kallenberg; P A Merkel; H Raspe; C Salvarani; D G I Scott; C Stegeman; R Watts; K Westman; J Witter; H Yazici; R Luqmani
Journal:  Ann Rheum Dis       Date:  2008-04-15       Impact factor: 19.103

4.  Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Kirsten De Groot; Niels Rasmussen; Paul A Bacon; Jan Willem Cohen Tervaert; Conleth Feighery; Gina Gregorini; Wolfgang L Gross; Raashid Luqmani; David R W Jayne
Journal:  Arthritis Rheum       Date:  2005-08

5.  Etanercept plus standard therapy for Wegener's granulomatosis.

Authors: 
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

6.  Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis.

Authors:  B Nölle; U Specks; J Lüdemann; M S Rohrbach; R A DeRemee; W L Gross
Journal:  Ann Intern Med       Date:  1989-07-01       Impact factor: 25.391

7.  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.

Authors:  David R W Jayne; Gill Gaskin; Niels Rasmussen; Daniel Abramowicz; Franco Ferrario; Loic Guillevin; Eduardo Mirapeix; Caroline O S Savage; Renato A Sinico; Coen A Stegeman; Kerstin W Westman; Fokko J van der Woude; Robert A F de Lind van Wijngaarden; Charles D Pusey
Journal:  J Am Soc Nephrol       Date:  2007-06-20       Impact factor: 10.121

8.  Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis.

Authors:  E Reinhold-Keller; J Kekow; A Schnabel; W H Schmitt; M Heller; A Beigel; G Duncker; W L Gross
Journal:  Arthritis Rheum       Date:  1994-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.